严谨·求实
制生物之精华，助科技之强盛
About us
All categories
History
-
2022
In February, Phloroglucinol injection passed the consistency evaluation (the first in China) -
2021
In May, the R&D building was completed and put into use In October, a postdoctoral workstation was established -
2020
In January, the name was changed to Wanbangde Pharmaceutical Group Co., Ltd. In February, Wanbangde was successfully restructured and listed (stock code 002082), and the pharmaceutical group entered the listed company system -
2019
In March, Wanbangde Pharmaceutical Group officially became a wholly-owned subsidiary of Wanbangde Pharmaceutical Holding Group Co., Ltd. -
2018
In June, the anti-Alzheimer's drug Huperzine A controlled-release tablet was approved for clinical trials In December, the academician expert workstation led by Academician Tang Xican was rated as "National Academician Workstation" -
2017
In April, the first domestic collaborative innovation alliance of medical research enterprises for pharmaceutical products was established - Ginkgo Leaf Dropping Pill Medical Research Enterprise Collaborative Innovation Alliance -
2016
In June, reached a strategic cooperation with the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences - the "Alzheimer's Disease New Drug FN12" project was signed -
2015
In January, a wholly-owned subsidiary, Hangzhou Pharmaceutical Technology Co., Ltd., was established In November, the academician expert workstation was established, and a cooperation agreement was signed with the team of academician Tang Xican. -
2014
In January, the Ginkgo Leaf Dropping Pill Building was completed and put into use In April, Wanbangde trademark was rated as "China Famous Trademark" In May, acquired Jiangsu Besikang Pharmaceutical Co., Ltd. In August, changed its name to Wanbangde Pharmaceutical Group Co., Ltd. In November, the company's technology center was rated as a provincial-level enterprise technology center; it was rated as a key high-tech enterprise in the National Torch Program -
2013
In October, the acquisition of Zhejiang Pharmaceutical Sales Co., Ltd. (Zhengyi Pharmaceutical) was a turning point in the start of sales -
2011
In February, Zhejiang Wanbang Pharmaceutical Co., Ltd. was changed to Zhejiang Wanbang Pharmaceutical Co., Ltd., and Wanbang entered the joint-stock system stage -
2010
In January, the acquisition of Wenling Shi Nihongda Auxiliary Factory In May, Ginkgo biloba dripping pills were listed as a project of the "2010 Torch Plan" of the Ministry of Science and Technology; the acquisition of Zhejiang Baijia Pharmaceutical Co., Ltd. In July, an API factory was established in Shangma Industrial Park, Wenling, which was a turning point in the development of APIs In September, acquired Ningbo Siming Pharmaceutical Co., Ltd. In December, the company was approved to establish the "Provincial High-tech Enterprise Research and Development Center for Cardiovascular and Cerebrovascular Drugs"; acquired the equity of Tongda Chemical -
2009
In July, the company was identified as a high-tech enterprise In August, the company's full intellectual property product, Ginkgo Leaf Dropping Pills, was listed as the leading product of technical preparations in Zhejiang Province; the company's full intellectual property product, Huperzine A, was listed as a potential cultivation product of pharmaceutical preparations in Zhejiang Province. -
2008
In May, acquired Tangshan Bohai Pharmaceutical Co., Ltd. -
2004
In April, the company's full intellectual property product, Ginkgo Biloba Dropping Pills, was approved for production by the State Food and Drug Administration (CFDA). In May, the factory was relocated, and the production capacity was doubled -
2002
In July, acquired Wenling Pharmaceutical Factory and changed its name to "Zhejiang Wanbang Pharmaceutical Co., Ltd." -
1970
Wenling Pharmaceutical Factory was established
Copyright 2016 © wanbang.com.cn All Rights Reserved.
Internet drug information service qualification certificate :(zhejiang) - non-operating -2023-0143 Powered by 300.cn
